Yes / It is 40 years since the publication of the patent that announced the imidazotetrazines temozolomide
and mitozolomide to the world and 30 since the discovery that they function as prodrugs
of alkyldiazonium reactive intermediates. Temozolomide combined with radiation is established as the
first-line treatment for glioma but despite the attentions of the inventors and others, further examples of
this intriguing ring system have yet to enter the clinic.
| Identifer | oai:union.ndltd.org:BRADFORD/oai:bradscholars.brad.ac.uk:10454/19592 |
| Date | 19 September 2023 |
| Creators | Stevens, M.F.G., Wheelhouse, Richard T. |
| Publisher | Royal Society of Chemistry |
| Source Sets | Bradford Scholars |
| Language | English |
| Detected Language | English |
| Type | Article, Published version |
| Rights | © 2023 The Author(s). This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence., CC-BY-NC |
Page generated in 0.0018 seconds